Advanced in Hypophosphatasia (HPP)

Richard W. Keen

Stanmore, ENG, GB 
Advanced in Hypophosphatasia (HPP)
Stanmore, ENG, GB 
OverviewLocationsClinical Research

Overview

Richard Keen practices in Stanmore, United Kingdom. Mr. Keen is rated as an Advanced expert by MediFind in the treatment of Hypophosphatasia (HPP). His top areas of expertise are Fibrodysplasia Ossificans Progressiva, Hypophosphatemia, X-Linked Hypophosphatemia, and Rickets.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypophosphatasia (HPP).

Gender
Male

Locations

Stanmore, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
Brockley Hill, Stanmore, Middlesex, ENG HA74LP, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drugs: Teriparatide, Zoledronic Acid
Study Phase: Phase 4
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Palovarotene
Study Phase: Phase 2
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: Palovarotene
Study Phase: Phase 3
Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, Using Spatially Offset Raman Spectroscopy
Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, Using Spatially Offset Raman Spectroscopy
Enrollment Status: Unknown
Publish Date: November 23, 2022
Intervention Type: Device
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: February 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: June 26, 2020
View 7 Less Clinical Trials

53 Total Publications

Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK.
Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK.
Journal: Calcified tissue international
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keen's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile